Clene announces $7M underwritten offering of 1M shares at $7.00 per share

Clene Inc.

Offering of 1,000,000 shares of common stock at $7.00/share; gross proceeds ~$7M.
Net proceeds estimated at ~$6.4M after underwriting discounts (~6.5%) and expenses (~$140K).
Proceeds to fund NDA preparation for CNM-Au8, Phase 3 trial, manufacturing, and commercialization.
Canaccord Genuity is sole bookrunner; Maxim Group and D. Boral Capital are financial advisors.
Insiders subject to 60-day lock-up; closing expected on May 6, 2026.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Clene Inc. entered into Underwriting Agreement with Canaccord Genuity LLC valued at 1,000,000 shares of common stock at $7.00 per share for estimated net proceeds of $6.4 million (effective 2026-05-05).

Action: entry
Agreement: underwriting
Counterparty: Canaccord Genuity LLC
Value: 1,000,000 shares of common stock at $7.00 per share for estimated net proceeds of $6.4 million
Effective: 2026-05-05

Exact text from the filing

On May 5, 2026, Clene Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Canaccord Genuity LLC as underwriter, pursuant to which the Company agreed to issue and sell an aggregate of 1,000,000 shares of the Company’s common stock, par value $0.0001 per share (“common stock”), at an offering price of $7.00 per share.

View on SEC.gov

Browse all material agreements →

Clene Inc. filing history →

Source: SEC EDGAR

accession 0001437749-26-014946

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.